Fig. 3From: Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case seriesChange of tumor burden in on-target lesions. Change of tumor burden from baseline (before T-VEC injection) in injected lesions for each patient is shown as a function time measured in weeks. The time of T-VEC injection is set at 0. End of line indicates time of observationBack to article page